Results of the ARCTIC-INTERRUPTION trial presented at TCT 2013

October 31, 2013

SAN FRANCISCO, CA - October 31, 2013 - According to a new study, patients that do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT). Results from the ARCTIC-INTERRUPTION trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The optimal length of time for DAPT after coronary stenting remains uncertain with an unknown safety to efficacy ratio of prolonged therapy. Currently there are discrepancies between international guidelines and high variability in routine practice. The ARCTIC-INTERRUPTION study was a prospective randomized trial that examined the benefit of the continuation of DAPT for up to two years.

ARCTIC-INTERRUPTION randomly assigned 1,259 patients without major events within the first year after coronary stenting to either a strategy of interruption of DAPT (n=624), or a strategy of continuation for an additional year (n=635). The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization after one year.

The primary endpoint occurred in 3.8 percent of patients in the continuation group, as compared to 4.3 percent in the interruption group. The main secondary endpoint of stent thrombosis or any urgent revascularization occurred in 1.3 percent of patients in the continuation group and 1.6 percent of those in the interruption group. The rate of major bleeding events occurred in 1.1 percent of the patients in the continuation group compared to 0.2 percent in the interruption group.

"The ARCTIC-INTERRUPTION study suggests no ischemic benefit of DAPT continuation beyond one year after stenting in patients that do not experience an adverse event within the first year," said lead investigator Gilles Montalescot, MD, PhD. Dr. Montalescot is Professor of Cardiology at Centre Hospitalier Universitaire Pitié-Salpêtrière in Paris, France.

"Further, the study found significantly more major and minor bleeding events with DAPT continuation."
-end-
The ARCTIC-INTERRUPTION trial was sponsored by the ACTION study group. Dr. Montalescot reported research grants to the institution or consulting/lecture fees from Abbott Vascular, Accumetrics, AstraZeneca, Bayer, Biotronik, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Duke Institute, Eli Lilly and Company, Europa, Fédération Française de Cardiologie, Fondation de France, GSK, INSERM, Institut de France, Iroko, Lead-up, Menarini, Medtronic, Nanospheres, Novartis, Pfizer, ReCor Medical, Roche, Sanofi-Aventis, Stentys, Société Française de Cardiologie, Springer, The Medicines Company, The TIMI group, WebMD, and Wolters.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.

Cardiovascular Research Foundation

Related Stent Thrombosis Articles from Brightsurf:

Early indications of thrombosis help in preventing postoperative complications
It is well-known that surgeries can be complicated by life-threatening thromboses that are hard to predict and not easy to prevent.

Standalone D-dimer test strategy may simplify diagnosis of deep vein thrombosis
New research suggests that it may be possible to simplify the diagnosis of deep vein thrombosis (DVT) without compromising accuracy.

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
In a systematic review of the worldwide published data on ''Venous thromboembolism (VTE) in COVID-19 patients'', researchers from the Department of Medicine I (MedUni Vienna), provide an in-depth analysis on the risk of VTE in patients hospitalised for COVID-19.

What is cerebral venous thrombosis? study finds blood clot condition on the rise
Cerebral venous thrombosis (CVT) occurs when a blood clot forms in one of the veins in the brain, preventing blood from draining out of the brain.

Late coronary stent thrombosis in patient with COVID-19
This case report describes a patient with COVID-19 who developed late drug-eluting stent thrombosis.

EULAR 2020: Thrombosis risk particularly high for people suffering
People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.

Venous thrombosis among critically ill patients with COVID-19
A systematic assessment of deep vein thrombosis among patients in an intensive care unit in France with severe COVID-19 is reported in this case series.

The world's smallest stent
Researchers at ETH Zurich have developed a new method for producing malleable microstructures -- for instance, vascular stents that are 40 times smaller than previously possible.

Type of stent affects immediate and long-term outcomes
A new study comparing the outcomes of different types of stents used to treat cerebral aneurysms shows that the type of stent used affects a patient's immediate and long-term health outcomes.

Read More: Stent Thrombosis News and Stent Thrombosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.